Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters











Database
Type of study
Language
Publication year range
1.
Clin Transl Oncol ; 12(1): 15-21, 2010 Jan.
Article in English | MEDLINE | ID: mdl-20080466

ABSTRACT

Renal cell carcinoma (RCC) is a heterogeneous malignancy whose incidence rate has notably increased in recent years without any evident reason. Traditionally, RCC has been resistant to classic treatments (chemotherapy, radiotherapy and hormonal therapy), with only a small percentage of patients benefiting from cytokine therapy. Different hereditary syndromes have been associated with RCC, Von Hippel Lindau (VHL) being the most important syndrome. Understanding key molecular pathways implicated in the tumorigenesis of RCC has crystallised in the development of more effective therapies. Specifically, drugs targeting VEGF (bevacizumab, sunitinib, sorafenib, axitinib, pazopanib) and PI3K-mTOR (temsirolimus and everolimus) have become the cornerstone of renal cancer treatment.


Subject(s)
Carcinoma, Renal Cell/genetics , Kidney Neoplasms/genetics , Animals , Antineoplastic Agents/administration & dosage , Carcinoma, Renal Cell/drug therapy , Carcinoma, Renal Cell/etiology , Drug Delivery Systems , Genetic Predisposition to Disease , Humans , Intracellular Signaling Peptides and Proteins/genetics , Kidney Neoplasms/drug therapy , Kidney Neoplasms/etiology , Protein Serine-Threonine Kinases/genetics , Signal Transduction/genetics , Syndrome , TOR Serine-Threonine Kinases , Vascular Endothelial Growth Factor A/genetics
SELECTION OF CITATIONS
SEARCH DETAIL